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ARTICLE
Analysis of exome data for 4293 trios suggests
GPI-anchor biogenesis defects are a rare cause of
developmental disorders
Alistair T Pagnamenta1, Yoshiko Murakami2,3, John M Taylor4, Consuelo Anzilotti5, Malcolm F Howard1,
Venessa Miller6, Diana S Johnson7, Shereen Tadros8, Sahar Mansour8, I Karen Temple9, Rachel Firth9,
Elisabeth Rosser10, Rachel E Harrison11, Bronwen Kerr12, Niko Popitsch1, The DDD Study13,
Taroh Kinoshita2,3, Jenny C Taylor1,14 and Usha Kini*,6,14
Over 150 different proteins attach to the plasma membrane using glycosylphosphatidylinositol (GPI) anchors. Mutations in 18
genes that encode components of GPI-anchor biogenesis result in a phenotypic spectrum that includes learning disability,
epilepsy, microcephaly, congenital malformations and mild dysmorphic features. To determine the incidence of GPI-anchor
defects, we analysed the exome data from 4293 parent–child trios recruited to the Deciphering Developmental Disorders (DDD)
study. All probands recruited had a neurodevelopmental disorder. We searched for variants in 31 genes linked to GPI-anchor
biogenesis and detected rare biallelic variants in PGAP3, PIGN, PIGT (n=2), PIGO and PIGL, providing a likely diagnosis for six
families. In ﬁve families, the variants were in a compound heterozygous conﬁguration while in a consanguineous Afghani
kindred, a homozygous c.709G4C; p.(E237Q) variant in PIGT was identiﬁed within 10–12 Mb of autozygosity. Validation and
segregation analysis was performed using Sanger sequencing. Across the six families, ﬁve siblings were available for testing and
in all cases variants co-segregated consistent with them being causative. In four families, abnormal alkaline phosphatase results
were observed in the direction expected. FACS analysis of knockout HEK293 cells that had been transfected with wild-type or
mutant cDNA constructs demonstrated that the variants in PIGN, PIGT and PIGO all led to reduced activity. Splicing assays,
performed using leucocyte RNA, showed that a c.336-2A4G variant in PIGL resulted in exon skipping and p.D113fs*2. Our
results strengthen recently reported disease associations, suggest that defective GPI-anchor biogenesis may explain ~0.15% of
individuals with developmental disorders and highlight the beneﬁts of data sharing.
European Journal of Human Genetics (2017) 25, 669–679; doi:10.1038/ejhg.2017.32; published online 22 March 2017
INTRODUCTION
In mammalian cells, there are thought to be over 150 different
proteins that are attached to the plasma membrane using a glycosyl-
phosphatidylinositol (GPI) anchor. This diverse family comprises
receptors, adhesion molecules and enzymes and is critical for normal
neuronal and embryonic development. The GPI anchor is synthesised
and remodelled in a complex series of biochemical reactions that take
place either in the endoplasmic reticulum (ER) or Golgi apparatus,
and at least 30 genes are known that encode components of this
pathway.1,2
The clinical signiﬁcance of this pathway was ﬁrst demonstrated in
1993 when somatic mutations in PIGA (which encodes subunit A of
phosphatidylinositol N-acetylglucosaminyltransferase) were shown to
cause paroxysmal nocturnal haemoglobinuria.3 This rare life-threatening
disease results from complement-mediated haemolysis due to a
deﬁciency of surface expression of GPI-anchored complement inhibi-
tors CD55 and CD59. At the time, it was speculated that constitutive
mutations in this gene would be embryonically lethal, however, this
turned out not to be the case and several overlapping phenotypes have
now been associated with germline variants.4–8
In 2014, using a combination of exome and targeted gene
sequencing, we identiﬁed three families where individuals with
learning disability and hyperphosphatasia harboured biallelic muta-
tions in PGAP3.9 Our work, together with results from many other
research groups worldwide, have suggested disease associations for at
least 18 genes that relate to GPI-anchor biosynthesis (Supplementary
Table S1) and the importance of testing this pathway in clinical
diagnostics is now increasingly recognised.2
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Although the phenotype associated with GPI-defects is variable,
global developmental delay is the most consistent ﬁnding
(Supplementary Table S1).10 Therefore, seeking to replicate our earlier
ﬁndings, determine the true incidence of GPI defects in a large
unbiased cohort and potentially to identify novel disease–gene
associations, we analysed data from the Deciphering Developmental
Disorders (DDD) study. This project is a collaboration between the
Wellcome Trust Sanger Institute and all 24 Regional Genetics Services
in the UK and the Republic of Ireland that aims to facilitate the
translation of genomic sequencing technologies into the National
Health Service. DDD’s analysis of an initial set of 1133 children with
severe undiagnosed developmental disorders revealed a genetic variant
that is likely to be causative in 317 cases,11 which provides consider-
able scope for providing diagnoses or identifying novel disease genes in
the remaining cases. The study has now identiﬁed at least 16 new
genes responsible for developmental disorders.12,13 Although recruit-
ment to this study ceased in April 2015, with more than 14 000
patients enrolled, the DDD study represents one of the largest exome
sequencing initiatives in the world.
MATERIALS AND METHODS
Recruitment and patient details
Patient recruitment was undertaken by all Regional Genetics Services in the UK
and the Republic of Ireland. Clinical details for the families of interest are
summarised in Table 1 and Supplementary Table S2. The DDD study has been
described in more detail elsewhere.11–13 More information about the aims of
the project, subject recruitment and a list of publications are available at www.
ddduk.org.
Exome analysis and DDD data ﬁltering
Exome sequencing and bioinformatic methods are described in the
Supplementary Methods. Potential candidate variants were identiﬁed in
individuals using VCF ﬁles generated by the DDD study and ﬁltering QC-
passed variants as follows:
 In an initial data set of 1133 trios, the minor allele frequency (MAF)
threshold was 1% for all inheritance models. To improve speciﬁcity in the
expanded data set of 4293 trios, the MAF threshold for monoallelic variants
was reduced to 0.1%.
 Variant effect predictor annotation had to suggest the most severe
consequence of the variant is protein altering.
 Inherited missense alterations predicted benign by PolyPhen-2 were
excluded.
 Genotype and inheritance had to be consistent with a monoallelic mode
(de novo or dominantly inherited from affected parent), biallelic mode
(homozygous or compound heterozygous) or X-linked mode (hemizygous).
Resulting candidate variants were then ﬁltered for the 31 genes listed in
Supplementary Table S1. For trios of interest, a list of all candidate variants was
provided. Additional genetic information available included full v4.1 VCFs,
annotation for variants that have already been reported back to clinicians via
DECIPHER14 and a list of Sanger validated de novo mutations called by
DeNovoGear.15 Selected BAM ﬁles were downloaded from the European
Genome-Phenome Archive (EGA; www.ebi.ac.uk/ega/datasets/EGAD00001001114).
Other information included clinical details, which included a list of Human
Phenome Ontology terms, information about family relationships and contact
details for the referring clinician. Additional information such as VCF ﬁles and
phenotypic data are available at www.ebi.ac.uk/ega/studies/EGAS00001000775
and the diagnostic variants have been made publicly available through the
DECIPHER database:
https://decipher.sanger.ac.uk/patient/257982#genotype
https://decipher.sanger.ac.uk/patient/259633#genotype
https://decipher.sanger.ac.uk/patient/258094#genotype
https://decipher.sanger.ac.uk/patient/270250#genotype
https://decipher.sanger.ac.uk/patient/270306#genotype
https://decipher.sanger.ac.uk/patient/263039#genotype
https://decipher.sanger.ac.uk/patient/277013#genotype
Re-analysis with alternative genome analysis pipeline
It is well known that there is a low genotype concordance between different
variant calling software.16 Therefore, data from three families where BAM ﬁles
were available in EGA were re-analysed with an analysis pipeline that combined
multi-sample variant calling with Platypus17 and variant prioritisation using
Ingenuity Variant Analysis (www.ingenuity.com/products/variant-analysis),
similar to that described previously.18 For three families where BAM ﬁles were
not available in EGA at the time of the analysis, we uploaded the VCF ﬁles that
had been generated from the DDD pipeline to Ingenuity Variant Analysis. We
ﬁltered variants looking for both de novo and recessive candidate variants using
a variety of settings to help conﬁrm that the GPI pathway variants that came up
from the primary analysis were the most likely candidates. Read alignments
supporting variants of interest were also viewed using the Integrative Genomics
Viewer (www.broadinstitute.org/igv).
Sanger validation
The genomic loci surrounding each of the putative pathogenic variants were
PCR ampliﬁed using the primers listed in Supplementary Table S3. PCRs were
puriﬁed using standard methods and bidirectional Sanger sequencing was
performed using BigDye chemistry (Applied Biosystems, Foster City, CA, USA).
Functional analysis of PIGN, PIGT and PIGO variants
PIGN-knockout HEK293 cells were generated and transfected as described
previously,19 with human wild-type or p.(L311W) mutant PIGN cDNA cloned
into pME, a strong SRα promoter-driven expression vector, or pTK, a medium
TK promoter-driven expression vector. PIGN constructs had an HA epitope tag
at the N terminus. After 3 days, restoration of the cell surface expression of
CD59 was evaluated by ﬂow cytometry. The strong promoter is useful for
detecting complete LoF and severe partial LoF, while the medium promoter is
helpful for detecting mild partial LoF because overexpression of mild partial
LoF mutant often causes full restoration of CD59.
Levels of expressed wild-type and p.(L311W) mutant HA-tagged PIGN in
pME-vector transfected cells were analysed by western blotting using an anti-
HA antibody (C29F4, Cell Signaling Tec, Danvers, MA, USA). Levels of protein
expression were normalised by the luciferase activity for transfection efﬁciencies
and by expression levels of GAPDH for loading controls.
PIGT and PIGO-knockout HEK293 cells were generated by CRISPR/Cas
system and the corresponding PIGT and PIGO variants were assessed by
measuring the restoration of CD59 surface expression. Western blotting was
used to analyse the protein levels. These experiments were performed as
described for PIGN, except PIGT cDNA constructs were FLAG-tagged at the
C-terminal and probed with anti-FLAG antibody (M2, Sigma-Aldrich, Saint
Louis, MO, USA).
Autozygosity analysis and calculation of inbreeding coefﬁcients
Allelic ratios from a set of high-quality variants were extracted as described in
the Supplementary Methods. These data were loaded into Nexus CN
(BioDiscovery, El Segundo, CA, USA) to call cnLOH segments across the
whole genome. We estimated the coefﬁcient of inbreeding as the total fraction
of the autosomal genome, which appeared to be homozygous by descent.
RNA analysis of PIGL splice variant
Fresh blood was collected into PAXgene Blood RNA Tubes and RNA
extractions were performed with the PAXGene Blood RNA kit (Qiagen,
Manchester, UK). cDNA was reverse transcribed using the QuantiTect kit
(Qiagen) and a mixture of oligo-dT and random primers. Forward primers
were designed in exons 1 and 2 while reverse primers were designed in exons 5
and 6 (Supplementary Table S3). RT-PCR products were diluted and run on a
High Sensitivity DNA Chip on the 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA). PCR products were also puriﬁed using exoI (NEB,
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Ipswich, MA, USA) and shrimp alkaline phosphatase (USB, Cleveland, OH,
USA) and Sanger sequencing was performed as described above.
RESULTS
Summary of candidates and exclusion criteria
The DDD ﬁltering pipeline identiﬁed 43 patient–parent trios (42
independent families and two siblings) in which rare, potentially
functional candidate variants were identiﬁed in at least one of the GPI-
anchor biogenesis genes. As has been noted previously,11 parental-
affected status signiﬁcantly inﬂuenced the number of candidate
variants identiﬁed. Across the entire exome, there were on average
65.8 candidate variants in trios where both parents were affected
(mostly variants inherited from one or other parent), 34.1 candidates
where just a single parent was affected and just 6.7 candidates (range
2–16) where neither parent was affected.
As of July 2015, four of the 43 index cases had variants in other
(ie, non-GPI pathway) genes reported that were already considered to
be clinically relevant. For instance, a girl with developmental delay and
ASD (DECIPHER ID 258536) harboured a de novo p.(Q1093*)
mutation in SYNGAP1 (NM_006772.2).20
GPI-anchor biogenesis genes reported to date (Supplementary
Table S1) are all associated with recessively inherited conditions.
We therefore focussed on variants that ﬁtted a biallelic inheritance
(ie, compound heterozygous or homozygous) or X-linked recessive
models, excluding families where parents were affected and candidate
variants ﬁtted a dominant inheritance model.
Focussing on a recessive model also led us to ignore putative
de novo missense variants in PIGM (c.1199A4G; p.(N400S),
NM_145167.2) and MPPE1 (c.682C4T; p.(R228C), NM_023075.5).
The inheritance pattern associated with PIGM mutations has been
reported to be autosomal recessive.21 We also note that both these
genes have low pLI scores in ExAC v0.3 and so are unlikely to be
sensitive to haploinsufﬁciency.22 After further review of candidates,
we also excluded a small set of variants, which were detected at MAF
0.1–1.0% but were each present in a homozygous state in ExAC V0.3
multiple times. This led us to exclude patients with biallellic variants in
PIGW (c.705C4G;705C4G in individual 275308, c.705C4G;
908G4A in 259553, NM_178517.3), PIGS (c.553C4T;553C4T in
267380, NM_033198.3) and GPLD1 (c.308A4G;2442delA in 276507,
NM_001503.3).
Overview of likely causative variants
As a result of the above ﬁltering, potentially clinically signiﬁcant
variants were identiﬁed in 7/4293 parent–child trios. These consisted
of 11 rare variants spread across ﬁve different GPI-anchor biogenesis
genes (Figure 1). In ﬁve of the families, the variants were in a
compound heterozygous conﬁguration. The sixth family was a
consanguineous Afghani kindred with two affected brothers and here
the likely causative mutation was homozygous.
Including the Afghani quartet, DNA from affected or unaffected
siblings was available for testing in four out of six of the families and
in all cases, the segregation pattern was consistent with the variants
being causative (Figure 1; P= 0.026). For four out of ﬁve genes where
alkaline phosphatase testing is known to be informative, abnormal
results were obtained and the directionality was as expected, that is,
elevated with mutations in three out of ﬁve genes, normal with one
out of ﬁve genes and lowered or close to lower limit with mutations in
one out of ﬁve genes (Table 1). None of the variants were reported to
occur in a homozygous state in ExAC, with total allele counts ranging
from 0 to 16 (Table 1).Ta
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PGAP3 family
Individual 257982 harboured rare compound heterozygous variants in
PGAP3: a c.914A4G (predicting a p.(D305G) alteration to the amino
acid sequence) inherited from the patient’s father and a c.320C4T
change (predicting p.(S107L)) from the mother. We note that
p.(D305G) was described previously (family B in Howard et al.9)
where it was shown to result in abnormal protein localisation to the
ER. p.(S107L) was identiﬁed in a more recent study where it was
shown to reduce PGAP3 activity.23 In one case (family D in Knauss
et al.23), the same two variants were identiﬁed as in 257982. However,
in that patient, p.(S107L) was paternal and p.(D305G) maternal.
Sanger sequencing conﬁrmed that both variants were present in the
affected brother of 257982 (Figure 1). In both affected siblings,
alkaline phosphatase activity was increased (Table 1), consistent with
the results reported previously.9
PIGN family
Individual 259633 harboured compound heterozygous variants in
PIGN: a c.932T4G (predicting p.(L311W)) from the father and a
c.694A4T (predicting p.(K232*)) from the mother. Sanger sequen-
cing of two unaffected siblings indicated that neither had inherited
both variants (Figure 1). Both variants have been described recently;
a homozygous p.(K232*) mutation was seen in a fetus diagnosed with
Fryns syndrome,24 a condition characterised by multiple congenital
anomalies, while p.(L311W) was observed in an individual where the
phenotype was limited to hypotonia, developmental delay and
seizures.25
Alkaline phosphatase testing for this case is uninformative as
normal results are expected for patients with PIGN mutations19,26
and therefore functional assessment was performed using PIGN-
knockout HEK293 cells. With an expression plasmid using a strong
pME promoter, a wild-type PIGN restored CD59 expression on
52% of PIGN-knockout cells after transient transfection, whereas
p.(L311W) PIGN restored CD59 on only 39% of the cells (Figure 2a,
left panel). With a medium promoter plasmid pTK, the wild-type
PIGN restored CD59 on a small fraction of the cells, whereas the
p.(L311W) PIGN had almost no effect (right panel). Western blot
analysis indicated that the missense alteration did not signiﬁcantly
affect protein expression (Figure 2b). These results indicate that the
p.(L311W) mutation reduces enzymatic activity rather than affecting
protein levels.
PIGT family 1
Individual 258094 harboured compound heterozygous variants in
PIGT: c.1582G4A (predicting p.(V528M)) from the mother and
c.1730dupC (predicting p.(L578fs*35)) from the father. Sanger
sequencing was used to validate both variants, although DNA from
the unaffected sister was unavailable for testing. Initial publications on
Figure 1 Pedigrees and genetic data for six families harbouring rare biallelic variants in genes encoding components of the GPI-anchor biogenesis pathway.
The Sanger sequencing traces shown are for the proband in each family and are shown in the coding direction, alongside the corresponding wild-type amino
acid sequence. In the case of PIGT family 2 we show a trace from the father, where the variant is in the heterozygous state. For PIGT family 1 and the PIGL
family, DNA was not available for the unaffected older siblings. Codon numbering is with respect to the following GenBank transcripts; PGAP3:
NM_033419.4; PIGN: NM_176787.4; PIGT: NM_015937.5; PIGO: NM_032634.3; PIGL: NM_004278.3.
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Figure 2 Follow-up studies on variants in PIGN and PIGT. (a) PIGN-knockout HEK293 cells were generated and transfected with human wild-type or
p.(L311W) mutant PIGN cDNA cloned into pME or pTK expression vectors. Restoration of the cell surface expression of CD59 was evaluated by ﬂow
cytometry. The mutant construct using the pME promoter did not rescue CD59 surface expression as efﬁciently as the wild-type construct, indicating that the
variant results in reduced PIGN activity. (b) Levels of expressed wild-type and p.(L311W) mutant HA-tagged PIGN in pME-vector transfected cells were
analysed by western blotting using an anti-HA antibody. After normalisation with luciferase activity and GAPDH, expression of the mutant protein appeared to
be reduced by only ~10% compared with the wild-type protein. (c) PIGT-knockout HEK293 cells were transfected with wild-type or mutant PIGT cDNA cloned
into pME or pTK expression vectors. Restoration of the cell surface expression of CD59 was evaluated by ﬂow cytometry. The mutant constructs using the pTK
promoter did not rescue CD59 surface expression as efﬁciently as the wild-type construct, indicating that the variants result in reduced PIGT activity.
(d) Levels of expressed wild-type and mutant FLAG-tagged PIGT in pME-vector transfected cells were analysed by western blotting. After normalisation,
expression of the mutant protein appeared to be reduced only for the p.(L578fs*35) variant. (e) Allelic ratio plots along chromosome 20 (for high conﬁdence
SNVs only) showed that the PIGT variant shared in 270250 and 270306 lies within a large region of autozygosity.
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this gene reported decreased alkaline phosphatase activity27,28 but a
subsequent study found normal levels.29 In this case, alkaline
phosphatase activity was in the normal range (Table 1). Rescue
experiments performed on PIGT-knockout HEK293 cells indicated
that both mutations result in a mild reduction in the amount of CD59
anchored to the cell membrane, although this effect was only seen
when using the pTK promoter (Figure 2c). Western blot analysis
suggested that p.(L578fs*35) may lead to a small decrease in protein
stability (Figure 2d). The functional effect of these two mutations was
further conﬁrmed by the reduced CD16 expression seen on patient
granulocytes (Supplementary Figure S1).
Recent studies have shown complex multisystem conditions can be
a result from blending of two distinct genetic disorders.30–33 In that
respect, we note that 258094 also harboured compound hetero-
zygous variants in PKHD1 (predicting p.(P2319Q); p.(D3923fs*8),
NM_138694.3). This gene is associated with Autosomal Recessive
Polycystic Kidney Disease (AR-PKD), a severe condition in which a
signiﬁcant fraction of babies die within the ﬁrst 4 weeks of life due to
breathing difﬁculties. Although 258094 had kidney stones, nephro-
lithiasis is not typically a feature of AR-PKD.
PIGT family 2
Individual 270250 harboured a homozygous c.709G4C variant
(predicting p.(E237Q)) in PIGT. An affected brother (270306) was
conﬁrmed by both Sanger sequencing and exome analysis to be
homozygous for the same variant (Figure 1). Alkaline phosphatase
activity for 270250 was below the normal range, whereas for the
younger brother it was at the lower end of the normal range (Table 1).
FACS analysis of PIGT-knockout HEK293 cells showed that
p.(E237Q) results in a small reduction in the amount of CD59
anchored to the cell membrane (Figure 2c).
Using allelic ratio information obtained from the exome data, we
estimated the coefﬁcients of inbreeding for 270250 and 270306 to be
1/15 and 1/19 respectively, consistent with the 1/16 theoretical
expectation for offspring of ﬁrst-cousin marriages. The PIGT gene
was shown to lie within a 10–12Mb region of autozygosity
(Figure 2e). The only larger region of autozygosity shared by both
siblings was a 35.5 Mb segment on the short arm of chromosome 2
(data not shown).
PIGO family
Individual 263039 harboured compound heterozygous variants in
PIGO: c.1306C4T (predicting p.(R436W)) from the mother and
c.713G4A (predicting p.(G238D)) from the father. The unaffected
elder brother did not have either variant. Alkaline phosphatase activity
was intermittently raised, as is expected.34 FACS analysis of PIGO-
knockout HEK293 cells showed that p.(G238D) resulted in no
detectable activity, consistent with its position within the Type 1
phosphodiesterase/nucleotide pyrophosphatase/phosphate transferase
domain and the conservation of Gly238 in known paralogues (PIGN
and PIGG). In contrast, p.(R436W) only resulted in a moderate
decrease in the amount of CD59 anchored to the cell membrane
(Figure 3a). The difference in functional effects could not be explained
by protein stability as both missense variants resulted in only a mild
decrease in protein expression (Figure 3b).
In addition, an X-linked variant of uncertain signiﬁcance
(c.2683T4A, predicting p.(F895I)) was identiﬁed in BCORL1
(NM_021946.4), a transcriptional co-repressor gene. Although this
variant is very rare and not present in ExAC, the evidence supporting
BCORL1 to be a causative gene for learning disability was limited;35
many of the proposed genes for X-linked learning disability have
recently been challenged in light of data from large exome sequencing
data sets.36
PIGL family
Individual 277013 harboured compound heterozygous variants in
PIGL: c.48G4A (predicting p.(W16*)) from the mother and a c.336-
2A4G mutation in the exon 3 consensus splice-acceptor site, from
the father. DNA from the unaffected brother was unavailable. Alkaline
phosphatase results were not reported in the original clinical descrip-
tion of CHIME syndrome37 but in a subsequent case with PIGL
mutations were described to be elevated.38 For 277013, alkaline
phosphatase levels were persistently raised (Table 1).
RNA analysis of the splice mutation was complicated by the fact
that in all the samples, we observed skipping of exon 5, consistent with
the Ensembl annotation ENST00000395844. Although this naturally
occurring isoform is predicted to result in a LoF allele (p.A166fs*80),
we note that this shorter transcript was observed at relatively low levels
when compared with the canonical mRNA (Supplementary
Figure S2). In view of this, we did not attempt to analyse the exon
3 splice-acceptor mutation using sequence from the ‘6 R’ RT-PCR
primer. The analysis of RT-PCR products using the ‘5 R’ primer
demonstrated that the c.336-2A4G mutation resulted in a lower band
in both 277013 and in her father (Figure 3c). Sanger sequencing
conﬁrmed that this was due to complete skipping of exon 3, predicting
a frameshift that results in an aspartic acid to tryptophan alteration
followed immediately by a premature stop (p.D113fs*2; Supplementary
Figure S3) and therefore likely represents a LoF allele.
Although the stop and splice variants are both seen in ExAC
(1/121 332 and 6/121 410, respectively), neither occur in a homo-
zygous state. There were also no other homozygous LoF variants in
PIGL within ExAC or another project that searched for rare gene
knockouts in a cohort enriched for homozygous alleles.39
Overall clinical comparison
Epilepsy and microcephaly was observed in 5/6 and 3/6 of the families,
respectively (Table 1). The photographs of patients (Figures 4a–d and
data not shown) highlight a number of common facial similarities,
most notably the thin tented upper lips and a broad nasal tip apparent
in three out of six of the families. Brachydactyly or brachytelephalangy
is present in three out of six of the families. This has been previously
reported with GPI mutations. Moderate-to-severe intellectual disability
is universal. Some patients were noted to have structural brain
anomalies such as cerebral atrophy, cerebellar atrophy and Dandy–
Walker variant. Other structural abnormalities seen were cleft palate,
aganglionic megacolon and renal cysts. Although not individually
common, these anomalies have also been previously described.
DISCUSSION
In this study, we interrogated exome data from 4293 patient–parent
trios, looking for rare biallelic variants in 31 genes related to GPI-
anchor biogenesis. Seven individuals (from six independent families)
were identiﬁed, each referred from different Regional Genetics Services
across the UK. As the 4293 patients came from 4125 independent
families,40 we therefore estimate incidence of GPI biogenesis defects in
this patient group to be ~ 0.15% (6/4125). Other studies on GPI-
anchor biogenesis have typically either used much tighter patient
selection criteria41 or else large consanguineous families where genetic
mapping is possible.9 This is therefore the ﬁrst study to estimate the
prevalence of such defects in a large unbiased cohort with
developmental delay.
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Together with other recent studies,23,42 our study serves to conﬁrm
the genotype–phenotype correlation for PGAP3 that we ﬁrst described
in 2014.9 Besides the elevated alkaline phosphatase, the most notice-
able features that overlap the ﬁve original cases are the broad nasal tip
and thin upper lips, which were seen in both 257982 and her younger
brother (Figure 4a). Future studies should test whether the distinct
craniofacial gestalt make this a clinically recognisable condition.
Midline hand movements similar to those described in family A in
Howard et al9 were reported in the younger brother. Here, the onset of
absence and startle seizures was at age 2 years, whereas in published
cases, onset was 1.5–23 years and included tonic–clonic and myoclonic
forms of epilepsy.9,23 Microcephaly was observed in 3 out of 13
published cases9 and in the family described here, a small head size
was reported only in the younger brother. Hypotonia was also present
in both siblings, consistent with the literature. The p.(D305G) and p.
(S107L) mutations have now both been described and so have already
been functionally validated.9,23 p.S107L lies close to two other reported
mutations (p.(G92D) and p.(P105R)) and so this region of the gene
may represent a hotspot for disease-causing mutations.
As well as conﬁrmation of recently reported genotype–phenotype
correlations, our study also helps to delineate the phenotypic range
associated with certain GPI-anchor biogenesis genes. For instance,
Hirschsprung’s disease (HD), which is a relatively common feature in
cases with ‘hyperphosphatasia with mental retardation syndrome’
(HPMRS1) due to PIGV mutations (OMIM #239300),43 has only
been reported in one individual with PIGO mutations (HPMRS2;
OMIM #614749).44 The HD diagnosis for 263039 therefore provides
additional evidence that intestinal disorders can be observed across
different genetic HPMRS subtypes. Although seizures were not
reported (at 2 years of age), in other respects such as the cupid’s-
bow-shaped upper lip, intermittently elevated alkaline phosphatase,
hypoplasia of distal phalanges, postnatal microcephaly and hearing
loss, the phenotype for 263039 appears to be similar to published
cases.34,44,45
Mutations in PIGV are thought to represent the major cause of
‘hyperphosphatasia with mental retardation syndrome’43 and so we
were surprised that this gene did not come up in our analysis. We
therefore investigated the possibility that we were being overly
stringent with our MAF ﬁlter. The most common PIGV mutation
(c.1022C4A; p.(A341E)) is categorised as probably damaging by
PolyPhen-2 and present in ~ 80% of affected families.43 However, in
ExAC, this variant is seen at a maximum MAF of 17/66 740 alleles
(0.025%; all heterozygous) within the non-Finnish European popula-
tion, well below not only the initial 1% cut-off for biallelic variants,
but also the 0.1% ﬁlter that we applied following manual review of
variants.
Although this study has helped replicate relatively new disease
genes, all ﬁve for which the primary disease association was published
Figure 3 Follow-up studies on variants in PIGO and PIGL. (a) PIGO-knockout HEK293 cells were transfected with wild-type, p.(R436W) or p.(G238D) PIGO
cDNA. Restoration of the cell surface expression of CD59 was evaluated by ﬂow cytometry. The p.(G238D) variant resulted in no detectable activity when
using the pME promoter. For the p.(R436W) variant, reduced CD59 surface expression was only observed when using the pTK promoter. (b) Levels of
expressed wild-type and mutant HA-tagged PIGO in pME-vector transfected cells were analysed by western blotting. After normalisation, expression of the
mutant protein appeared to be mildly reduced for both missense variants. (c) 2100 Bioanalyser image showing PIGL RT-PCR amplicons using primers
positioned in exons 2 and 5. A lower band was observed for 277013 and her father, consistent with skipping of exon 3. The expected sizes were calculated
to be 280 bp and 189 bp if exon 3 is missing, which is consistent with the observed sizes given the margin for error reported by the manufacturer. Skipping
of a 91 bp exon would lead to a frameshift and premature termination codon, as shown in Supplementary Figure S3.
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since 2011 (Table 1), we were unable to identify likely causative
variants in any of the 13 genes in the GPI-anchor biogenesis pathway
for which disease associations have not yet been reported. It may be
that these genetic conditions are so rare that a larger cohort is needed
to identify such families. Alternatively, individuals with variants in
other GPI genes might not present with developmental delay. For
instance, a recent study suggests that mutations in PIGC are
embryonically lethal.46
One limitation of this study is that missense alterations predicted
benign by PolyPhen-2 would be missed. We also excluded variants,
which appeared homozygous multiple times within the ExAC cohort.
Although we felt these ﬁlters were necessary to improve speciﬁcity
while analysing such a large cohort, it means that our ~ 0.15%
estimate of incidence may represent an underestimate. We also
acknowledge that our use of WES (rather than WGS) would miss
deep intronic variants or structural variants such as inversions. In
particular, we cannot exclude that the de novo variants in PIGM and
MPPE1 occurred in trans with one such variant. Our understanding of
GPI-anchor biogenesis in humans may be incomplete. Additional
genes involved with this pathway may await discovery and so our
candidate gene list should be considered a non-exhaustive list. This
could again contribute to an underestimation of the true incidence.
Another limitation is that in most cases we were unable to perform
FACS analysis to assess levels of GPI-anchored proteins on patient
granulocytes, instead relying on phenotypic overlap, segregation
testing, alkaline phosphatase activity and functional results from
HEK293 cells to accumulate evidence supporting pathogenicity. For
all ﬁve genes identiﬁed, multiple families are already described in the
literature. As the phenotypes of the patients described here showed
signiﬁcant overlaps with published cases, we felt that once the variants
had been validated, requesting further venepunctures was not war-
ranted. The only exception to this was the girl from PIGT family 1,
where alkaline phosphatase results were normal and phenotypic
overlap was nonspeciﬁc. For this case, FACS analysis of patient
granulocytes indicated a mild decrease in surface CD16 levels. For
the girl with PIGN variants, the clinical overlap with published cases
also showed limited speciﬁcity. Biallelic variants in PIGN cause
‘multiple congenital anomalies-hypotonia-seizures syndrome type 1’
(MCAHS1; OMIM 614080).19,26 However, a recent review of pub-
lished cases highlights signiﬁcant phenotypic heterogeneity.24
Although seizures, developmental delay and hypotonia are always
present, other features can include dysmorphisms (low-set ears,
micrognathia and distal digital hypoplasia), cerebellar atrophy, nys-
tagmus and diaphragmatic hernia. Therefore, although the phenotype
observed for individual 259633 (epilepsy, developmental delay, hypo-
tonia and mild brain atrophy) does overlap, we considered the
Figure 4 Clinical images, shown with parental consent. (a) Photographs of individual 257982 aged 2 years and 8 months and her younger affected brother
both showing thin upper lip and short nose with a broad nasal tip. Arrow indicates cleft palate, shown for younger sibling but also present in proband.
(b) Photograph of 259633 showing thin tented upper lip and a short nose with a broad nasal tip. (c) Photographs of 258094 showing thin upper lip, nose
with broad nasal tip and low-set ears; hands show tapering ﬁngers. (d) Photograph of 263039 showing thin Cupid’s-bow shaped upper lip, brachydactyly with
absent ﬁfth ﬁngernail and dystrophic fourth and ﬁfth toenails.
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presentation to be nonspeciﬁc. In addition, for PIGN mutations,
alkaline phosphatase testing is not informative as PIGN deﬁcient
individuals do not have hyperphosphatasia. This may be because GPI
lacking an EtNP-side branch on Man1 is efﬁciently added to ALP
when GPI transamidase cleaves the GPI-attachment signal sequence.47
Using PIGN-knockout HEK293 cells, we conﬁrmed that p.(L311W)
results in reduced PIGN activity. Jezela-Stanek et al.25 recently
described a similar case with a relatively mild phenotype (seizures,
developmental delay and hypotonia) and reduced expression of
GPI-APs in patient granulocytes. It is interesting to note that the
p.(L311W) variant is also shared in common between these two
milder cases. Although p.(L311W) appears to retain some activity,
p.(K232*) in contrast is presumably a LoF allele and this might explain
why homozygosity of the p.(K232*) variant resulted in the severe
prenatal presentation reported recently by McInerney-Leo et al.24
To facilitate the consistent interpretation of genetic variants between
different clinical genetics laboratories, the American College of
Medical Genetics and Genomics (ACMG) has developed detailed
guidelines about how variants should be interpreted in a systematic
way.48 Using this scoring system, we classiﬁed the 11 variants
described in Figure 1 and note that seven of these variants are scored
as pathogenic, whereas for four of the variants there is only enough
evidence to reach a ‘likely pathogenic’ classiﬁcation (Supplementary
Table S4). A recent study showed that even following these recom-
mendations, variant scoring can be inconsistent. Although consensus
meetings can improve concordance between laboratories, agreement is
not always reached for many variants and further clariﬁcations may be
beneﬁcial.49 The scoring scheme allows a degree of ﬂexibility and
certain criteria can be increased in evidence strength based on expert
judgement. For example, both PGAP3 variants described here have
now been described in trans with pathogenic variants in three
unrelated patients and so the PM3 criteria should be upgraded from
moderate to strong. In two cases, we upgraded an inferred classiﬁca-
tion of ‘likely pathogenic’ to ‘pathogenic’. For instance, although the
p.(L311W) variant in PIGN has been described before,25 this was only
in a single affected individual and so we could not invoke PS4, which
requires multiple prior observations. But together with the modest
co-segregation seen in our family (again, not reaching the level to
invoke PP1) and the robust functional experiments performed here
using mutant HEK293 cells (Figure 2) and by Jezela-Stanek using
patient cells, this was enough to persuade us that this variant is
pathogenic.
In conclusion, our study suggests that defective GPI-anchor
biogenesis may explain ~ 0.15% of cases with developmental delay
and increases the yield of clinically relevant ﬁndings within the DDD
patient group that are available for families to help with recurrence
risk counselling and potentially the provision of further genetic testing.
The results also help conﬁrm and extend the phenotypic range of
recently reported disease genes and exemplify the beneﬁts of large scale
data sharing, providing a model for other large genomic projects such
as the UK’s 100 K genomes project.
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